Stoke Therapeutics Presents Data From Multiple Studies Of Children And Adolescents With Dravet Syndrome At The American Epilepsy Society 2023 Annual Meeting
– Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for
